Plain-English translation of NCT06970665 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a follow-up study in Japan testing ASP3021, a medication given as injections into the eye to help slow vision loss caused by geographic atrophy, a condition related to age-related macular degeneration. The medication has already been approved in Japan, and this study will continue to monitor how safe and effective it is in real-world use. Researchers will track changes in your vision and eye health over 12 months.
Geographic atrophy causes progressive vision loss that can severely impact quality of life, and currently there are very limited treatment options. This study continues to gather safety information about this new treatment to make sure it remains safe for patients using it.
You would receive regular injections of the medication directly into your eye over the 12-month study period. You would attend multiple clinic visits for eye exams, imaging tests (like photographs and scans of the back of your eye), and vision checks to monitor how you're responding to the treatment. The study is actively recruiting only in Japan and will track any side effects while measuring changes in your vision and the size of the affected area.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Japan